Evaluation of FGFR Alteration Status in Urothelial Tumors
- 7 July 2023
- book chapter
- Published by Springer Nature
- Vol. 2684, 283-291
Abstract
FGFR alterations in urothelial carcinoma are key driver alterations of tumorigenesis and are long recognized. In 2019 the Food and Drug Administration (FDA) approved the first pan-FGFR inhibitor, as the first specific targeted therapy in urothelial carcinoma. To receive the drug, alteration testing is required, and only alteration carriers can profit of this new agent. Due to this clinical need of detection and analysis of FGFR, here we describe two distinct and specific analytical methodologies: the SNaPshot analysis of nine FGFR3 point mutations and the QIAGEN therascreen® FGFR RGQ RT-PCR Kit, the FDA-approved companion diagnostic kit. Key words FGFR testing Urothelial carcinoma Inhibitor Targeted therapy SNaPshot analysis QIAGEN therascreen® FGFR RGQ RT-PCR KitKeywords
This publication has 10 references indexed in Scilit:
- Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and BiomarkersCancers, 2021
- Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?Cancers, 2021
- European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 GuidelinesEuropean Urology, 2021
- The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptorCancer Treatment Reviews, 2020
- Pure Large Nested Variant of Urothelial Carcinoma (LNUC) Is the Prototype of an FGFR3 Mutated Aggressive Urothelial Carcinoma with Luminal-Papillary PhenotypeCancers, 2020
- Erdafitinib in Locally Advanced or Metastatic Urothelial CarcinomaNew England Journal of Medicine, 2019
- Achondroplasia: Development, pathogenesis, and therapyDevelopmental Dynamics, 2016
- Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversityNature Reviews Cancer, 2014
- The FGF family: biology, pathophysiology and therapyNature Reviews Drug Discovery, 2009
- A Simple and Fast Method for the Simultaneous Detection of Nine Fibroblast Growth Factor Receptor 3 Mutations in Bladder Cancer and Voided UrineClinical Cancer Research, 2005